Article open access publication

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.

mAbs, Taylor & Francis, ISSN 1942-0870

Volume 7, 2, 2015

DOI:10.1080/19420862.2015.1007813, Dimensions: pub.1058413271, PMC: PMC4622648, PMID: 25760767,



  1. (1) Genmab (Netherlands), grid.466767.2
  2. (2) VU University Medical Center, grid.16872.3a
  3. (3) Department of Clinical Chemistry and Hematology; University Medical Center, ; Utrecht, The Netherlands
  4. (4) Department of Cell Biology; University Medical Center, ; Utrecht, The Netherlands
  5. (5) Department of Immunology; University Medical Center, ; Utrecht, The Netherlands
  6. (6) Leiden University Medical Center, grid.10419.3d
  7. (7) University of Southern Denmark, grid.10825.3e, SDU







Daratumumab (DARA) is a human CD38-specific IgG1 antibody that is in clinical development for the treatment of multiple myeloma (MM). The potential for IgG1 antibodies to induce macrophage-mediated phagocytosis, in combination with the known presence of macrophages in the tumor microenvironment in MM and other hematological tumors, led us to investigate the contribution of antibody-dependent, macrophage-mediated phagocytosis to DARA's mechanism of action. Live cell imaging revealed that DARA efficiently induced macrophage-mediated phagocytosis, in which individual macrophages rapidly and sequentially engulfed multiple tumor cells. DARA-dependent phagocytosis by mouse and human macrophages was also observed in an in vitro flow cytometry assay, using a range of MM and Burkitt's lymphoma cell lines. Phagocytosis contributed to DARA's anti-tumor activity in vivo, in both a subcutaneous and an intravenous leukemic xenograft mouse model. Finally, DARA was shown to induce macrophage-mediated phagocytosis of MM cells isolated from 11 of 12 MM patients that showed variable levels of CD38 expression. In summary, we demonstrate that phagocytosis is a fast, potent and clinically relevant mechanism of action that may contribute to the therapeutic activity of DARA in multiple myeloma and potentially other hematological tumors.

Research Categories

Main Subject Area

Fields of Research

Links & Metrics

NORA University Profiles

University of Southern Denmark

Danish Open Access Indicator

2015: Unused

Research area: Medicine

Dimensions Citation Indicators

Times Cited: 208

Field Citation Ratio (FCR): 39.67

Relative Citation ratio (RCR): 9.15

Open Access Info